Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States.
Elife. 2022 Feb 28;11:e74338. doi: 10.7554/eLife.74338.
The Fbw7 ubiquitin ligase targets many proteins for proteasomal degradation, which include oncogenic transcription factors (TFs) (e.g., c-Myc, c-Jun, and Notch). Fbw7 is a tumor suppressor and tumors often contain mutations in , the gene that encodes Fbw7. The complexity of its substrate network has obscured the mechanisms of Fbw7-associated tumorigenesis, yet this understanding is needed for developing therapies. We used an integrated approach employing RNA-Seq and high-resolution mapping (cleavage under target and release using nuclease) of histone modifications and TF occupancy (c-Jun and c-Myc) to examine the combinatorial effects of misregulated Fbw7 substrates in colorectal cancer (CRC) cells with engineered tumor-associated null or missense mutations. Both Fbw7 mutations caused widespread transcriptional changes associated with active chromatin and altered TF occupancy: some were common to both Fbw7 mutant cell lines, whereas others were mutation specific. We identified loci where both Jun and Myc were coregulated by Fbw7, suggesting that substrates may have synergistic effects. One coregulated gene was , the master regulator of MHC Class II gene expression. Fbw7 loss increased MHC Class II expression and Fbw7 mutations were correlated with increased CIITA expression in TCGA colorectal tumors and cell lines, which may have immunotherapeutic implications for Fbw7-associated cancers. Analogous studies in neural stem cells in which had been acutely deleted closely mirrored the results in CRC cells. Gene set enrichment analyses revealed Fbw7-associated pathways that were conserved across both cell types that may reflect fundamental Fbw7 functions. These analyses provide a framework for understanding normal and neoplastic context-specific Fbw7 functions.
Fbw7 泛素连接酶将许多蛋白质靶向到蛋白酶体降解,其中包括致癌转录因子(TFs)(例如 c-Myc、c-Jun 和 Notch)。Fbw7 是一种肿瘤抑制因子,肿瘤通常包含编码 Fbw7 的 基因的突变。其底物网络的复杂性掩盖了 Fbw7 相关肿瘤发生的机制,但为了开发治疗方法,这种理解是必要的。我们使用了一种综合方法,结合 RNA-Seq 和高分辨率的组蛋白修饰和 TF 占据(c-Jun 和 c-Myc)切割目标和释放(使用核酸酶),来研究具有工程肿瘤相关 缺失或错义突变的结直肠癌(CRC)细胞中失调的 Fbw7 底物的组合效应。两种 Fbw7 突变都导致了与活性染色质和改变的 TF 占据相关的广泛转录变化:有些是两种 Fbw7 突变细胞系共有的,而有些则是突变特异性的。我们确定了 Fbw7 共同调节 Jun 和 Myc 的基因座,表明底物可能具有协同作用。一个共同调节的基因是 ,这是 MHC 类 II 基因表达的主要调节因子。Fbw7 缺失增加了 MHC 类 II 的表达,并且 Fbw7 突变与 TCGA 结直肠肿瘤和细胞系中 CIITA 表达的增加相关,这可能对 Fbw7 相关癌症的免疫治疗具有意义。在急性缺失 的神经干细胞中的类似研究与 CRC 细胞的结果非常相似。基因集富集分析揭示了在两种细胞类型中都保守的 Fbw7 相关途径,这可能反映了 Fbw7 的基本功能。这些分析为理解正常和肿瘤特定的 Fbw7 功能提供了一个框架。